Literature DB >> 32762901

Loop Diuretic Prescription and 30-Day Outcomes in Older Patients With Heart Failure.

Charles Faselis1, Cherinne Arundel2, Samir Patel3, Phillip H Lam4, Stephen S Gottlieb5, Michael R Zile6, Prakash Deedwania7, Gerasimos Filippatos8, Helen M Sheriff3, Qing Zeng3, Charity J Morgan9, Samuel Wopperer10, Tran Nguyen3, Richard M Allman11, Gregg C Fonarow12, Ali Ahmed13.   

Abstract

BACKGROUND: Heart failure (HF) is a major source of morbidity and mortality. Fluid retention and shortness of breath are its cardinal manifestations for which loop diuretics are used. Although their usefulness is well accepted, less is known about their role in improving clinical outcomes.
OBJECTIVES: The purpose of this study was to determine the relationship between loop diuretics and clinical outcomes in patients with HF.
METHODS: Of the 25,345 older patients hospitalized for HF in the Medicare-linked OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry, 9,866 (39%) received no pre-admission diuretics. The study excluded 1,083 patients receiving dialysis and 847 discharged on thiazide diuretics. Of the remaining 7,936 patients, 5,568 (70%) were prescribed loop diuretics at discharge. Using propensity scores for receipt of loop diuretics estimated for each of the 7,936 patients, a matched cohort of 2,191 pairs of patients was assembled balanced on 74 baseline characteristics. Hazard ratios (HRs) and 95% confidence intervals (CIs) for outcomes were estimated in the matched cohort.
RESULTS: Matched patients (n = 4,382) had a mean age of 78 years, 54% were women, and 11% were African American. The 30-day all-cause mortality occurred in 4.9% (107 of 2,191) and 6.6% (144 of 2,191) of patients in the loop diuretic and no loop diuretic groups, respectively (HR when the use of loop diuretics was compared with nonuse: 0.73; 95% CI: 0.57 to 0.94; p = 0.016). Patients in the loop diuretic group had a significantly lower risk of 30-day HF readmission (HR: 0.79; 95% CI: 0.63 to 0.99; p = 0.037) but not of 30-day all-cause readmission (HR: 0.89; 95% CI: 0.79 to 1.01; p = 0.081). None of the associations was statistically significant during 60 days of follow-up.
CONCLUSIONS: Hospitalized older patients not taking diuretics prior to hospitalization for HF decompensation who received a discharge prescription for loop diuretics had significantly better 30-day clinical outcomes than those not discharged on loop diuretics. These findings provide new information about short-term clinical benefits associated with loop diuretic use in HF. Published by Elsevier Inc.

Entities:  

Keywords:  heart failure; loop diuretics; outcomes

Mesh:

Substances:

Year:  2020        PMID: 32762901      PMCID: PMC9067440          DOI: 10.1016/j.jacc.2020.06.022

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   27.203


  27 in total

1.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  J Am Coll Cardiol       Date:  2013-06-05       Impact factor: 24.094

Review 2.  Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review.

Authors:  G Michael Felker; David H Ellison; Wilfried Mullens; Zachary L Cox; Jeffrey M Testani
Journal:  J Am Coll Cardiol       Date:  2020-03-17       Impact factor: 24.094

3.  Comparative effectiveness of diuretic regimens.

Authors:  Gregg C Fonarow
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

Review 4.  Diuretic Treatment in Heart Failure.

Authors:  David H Ellison; G Michael Felker
Journal:  N Engl J Med       Date:  2017-11-16       Impact factor: 91.245

5.  Design and rationale of studies of neurohormonal blockade and outcomes in diastolic heart failure using OPTIMIZE-HF registry linked to Medicare data.

Authors:  Yan Zhang; Meredith L Kilgore; Tarun Arora; Marjan Mujib; O James Ekundayo; Inmaculada B Aban; Margaret A Feller; Ravi V Desai; Thomas E Love; Richard M Allman; Gregg C Fonarow; Ali Ahmed
Journal:  Int J Cardiol       Date:  2011-11-25       Impact factor: 4.164

6.  Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial.

Authors:  Ali Ahmed; Michael W Rich; Thomas E Love; Donald M Lloyd-Jones; Inmaculada B Aban; Wilson S Colucci; Kirkwood F Adams; Mihai Gheorghiade
Journal:  Eur Heart J       Date:  2005-12-08       Impact factor: 29.983

7.  The effects of oral ibopamine in patients with mild heart failure--a double blind placebo controlled comparison to furosemide. The Ibopamine Study Group.

Authors:  J O Parker
Journal:  Int J Cardiol       Date:  1993-07-15       Impact factor: 4.164

8.  A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study.

Authors:  Mustafa I Ahmed; Michel White; O James Ekundayo; Thomas E Love; Inmaculada Aban; Bo Liu; Wilbert S Aronow; Ali Ahmed
Journal:  Eur Heart J       Date:  2009-06-16       Impact factor: 29.983

9.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.

Authors:  Gregg C Fonarow; Wendy Gattis Stough; William T Abraham; Nancy M Albert; Mihai Gheorghiade; Barry H Greenberg; Christopher M O'Connor; Jie Lena Sun; Clyde W Yancy; James B Young
Journal:  J Am Coll Cardiol       Date:  2007-08-06       Impact factor: 24.094

10.  Estimating the effect of treatment on binary outcomes using full matching on the propensity score.

Authors:  Peter C Austin; Elizabeth A Stuart
Journal:  Stat Methods Med Res       Date:  2015-09-01       Impact factor: 3.021

View more
  4 in total

1.  Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program.

Authors:  Jie Yu; Clare Arnott; Brendon L Neuen; Hiddo L Heersprink; Kenneth W Mahaffey; Christopher P Cannon; Sadiya S Khan; Abigail S Baldridge; Sanjiv J Shah; Yuli Huang; Chao Li; Gemma A Figtree; Vlado Perkovic; Meg J Jardine; Bruce Neal; Mark D Huffman
Journal:  ESC Heart Fail       Date:  2021-02-17

2.  Prognostic impact of systolic blood pressure in acute heart failure with preserved ejection fraction in older patients.

Authors:  Sophie Putot; Arthur Hacquin; Patrick Manckoundia; Alain Putot
Journal:  ESC Heart Fail       Date:  2021-10-19

3.  Trial of Oral Diuretics Prior to Discharge Is Not Associated With Improved Outcomes in Decompensated Heart Failure.

Authors:  Adeba Mohammad; Shuktika Nandkeolyar; Dennis Grewal; Antoine Sakr; Ahmed Seliem; Liset Stoletniy; Dmitry Abramov
Journal:  Cardiol Res       Date:  2021-07-09

4.  Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension.

Authors:  Charles Faselis; Phillip H Lam; Michael R Zile; Poonam Bhyan; Apostolos Tsimploulis; Cherinne Arundel; Samir Patel; Peter Kokkinos; Prakash Deedwania; Deepak L Bhatt; Qing Zeng-Trietler; Charity J Morgan; Wilbert S Aronow; Richard M Allman; Gregg C Fonarow; Ali Ahmed
Journal:  Am J Med       Date:  2020-09-30       Impact factor: 4.965

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.